Loading data for IBRX — first visit, this takes a few seconds.

알림

ImmunityBio Inc. (IBRX)

NasdaqGS: IBRX · 실시간 가격 · USD

7.79

-0.05 (-0.64%)

종가 기준: Aug 21, 2026, 8:00 PM

7.78

-0.13%

애프터마켓: 7:59 PM

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

-0.64% (1D)

데이터 없음

매수호가	5.66
시가총액	8.26B
매출 (ttm)	165.79M
순이익 (ttm)	-992.36M
	0.12
	-0.95
	n/a
	-61.5
P/B (ttm)	-7.84
P/S (ttm)	49.80
실적 발표일	n/a

매도호가	8.92
거래량	7,462,325
평균 거래량 (20일)	11,089,604
시가	7.85
전일 종가	7.84
일중 범위	7.61 - 7.95
52주 범위	1.95 - 12.43
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

IBRX 소개

ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated ...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Jul 28, 2015

직원 수 684

상장 거래소 NasdaqGS

티커 IBRX

웹사이트 https://immunitybio.com

전체 기업 정보

재무 실적

2025년 ImmunityBio의 매출은 113.29M로, 전년 14.74M 대비 668.31% 증가했습니다. 순이익은 -351.4M로, -15.03% 감소했습니다.

재무제표

어닝 서프라이즈

ImmunityBio가 Aug 4, 2026에 분기 실적을 발표했습니다:

매출 $51.24M 예상치 하회 $0, 및 93.91% 전년 대비 성장.
EPS -0.22 예상치 하회 -0.14, 및 -120.00% 전년 대비 감소.

뉴스

1일 전 · Stocktwits

SLS, IBRX Stocks In Focus: Analyst Says Moderna-Merck Cancer Vaccine Success ‘Bodes Well’ For Oncology

Moderna soared 177% Wednesday, while Merck gained 13% and the rally spread to BioNTech, Arcturus, Tempus AI and Novavax.

5일 전 · Stocktwits

Goldman Sachs Builds $75M Bet Across CAPR, SLS And IBRX As Major Catalysts Loom

Goldman increased its stake in Sellas by 5.2% to 585,035 shares, worth $8.64 million.

1주 전 · Stocktwits

SLS And IBRX Eye Green Weekly Close: Vanguard’s Major Stakes In Cancer Drugmakers Steal The Spotlight

Vanguard held SLS and IBRX positions worth a combined $259 million at quarter-end.

2주 전 · Simply Wall St.

ImmunityBio (IBRX) Stock Looks Rich On Sales But Strong On Returns

ImmunityBio stock has delivered a very strong 321.9% return over the past three years, yet current valuation checks and recent price weakness raise questions about how much of the recent progress is a...

2주 전 · Simply Wall St.

The Bull Case For ImmunityBio (IBRX) Could Change Following ANKTIVA’s Broad UAE Approval And Ongoing Losses

In the past week, ImmunityBio, Inc. received marketing authorization in the United Arab Emirates for ANKTIVA across BCG-unresponsive non-muscle invasive bladder cancer and metastatic non-small cell lu...

2 페이지 중 1

ImmunityBio Inc. (IBRX)